Wedbush Has Pessimistic View of Nuvation Bio Q3 Earnings

Nuvation Bio Inc. (NYSE:NUVB) – Wedbush cut their Q3 2025 earnings estimates for Nuvation Bio in a research report issued on Monday, March 3rd. Wedbush analyst D. Nierengarten now anticipates that the company will post earnings of ($0.17) per share for the quarter, down from their previous forecast of ($0.16). Wedbush has a “Outperform” rating and a $5.00 price objective on the stock. The consensus estimate for Nuvation Bio’s current full-year earnings is ($0.36) per share. Wedbush also issued estimates for Nuvation Bio’s Q4 2025 earnings at ($0.19) EPS, FY2025 earnings at ($0.62) EPS, FY2026 earnings at ($0.73) EPS and FY2027 earnings at ($0.48) EPS.

Several other brokerages also recently weighed in on NUVB. HC Wainwright upped their target price on shares of Nuvation Bio from $10.00 to $11.00 and gave the company a “buy” rating in a research note on Thursday, January 23rd. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $10.00 price target (up from $6.00) on shares of Nuvation Bio in a report on Tuesday, January 7th. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Nuvation Bio currently has an average rating of “Buy” and a consensus target price of $8.20.

Nuvation Bio Trading Up 3.6 %

Shares of NUVB stock opened at $1.89 on Thursday. The company has a market capitalization of $634.43 million, a PE ratio of -0.87 and a beta of 1.47. The firm has a fifty day simple moving average of $2.44 and a 200-day simple moving average of $2.60. Nuvation Bio has a twelve month low of $1.67 and a twelve month high of $4.16.

Institutional Trading of Nuvation Bio

Large investors have recently modified their holdings of the company. Forum Financial Management LP acquired a new stake in shares of Nuvation Bio in the 4th quarter worth about $29,000. Cerity Partners LLC acquired a new stake in shares of Nuvation Bio in the 4th quarter worth about $31,000. Russell Investments Group Ltd. increased its holdings in shares of Nuvation Bio by 15,183.7% in the 4th quarter. Russell Investments Group Ltd. now owns 15,895 shares of the company’s stock worth $42,000 after acquiring an additional 15,791 shares during the period. Abacus Planning Group Inc. acquired a new stake in shares of Nuvation Bio in the 4th quarter worth about $44,000. Finally, Cibc World Markets Corp bought a new position in Nuvation Bio in the 4th quarter valued at about $45,000. Institutional investors and hedge funds own 61.67% of the company’s stock.

About Nuvation Bio

Nuvation Bio Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer.